Neurofilament light chain protein in neurodegenerative dementia: A systematic review and network meta-analysis

Zhao, Yinan; Xin, Yanguo; Su, Meng; He, Zhiyi; Hu, Wen‐Yu

doi:10.1016/j.neubiorev.2019.04.014

Cited by 73 publications

(57 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Serum NfL concentrations, as already demonstrated in other neurodegenerative disorders (Bridel et al, 2019;Forgrave et al, 2019;Zhao et al, 2019), were associated with measures of disease severity, and are helpful in assessing disease stage. In fact, higher serum NfL levels were significantly associated with more pronounced cognitive impairment and behavioural disturbances.…”

Section: Discussionsupporting

confidence: 52%

Diagnostic and prognostic value of serum NfL and p-Tau₁₈₁in frontotemporal lobar degeneration

Benussi

Karikari

Ashton

et al. 2020

J Neurol Neurosurg Psychiatry

106

112

View full text Add to dashboard Cite

ObjectiveTo assess the diagnostic and prognostic value of serum neurofilament light (NfL) and serum phospho-Tau181 (p-Tau181) in a large cohort of patients with frontotemporal lobar degeneration (FTLD).MethodsIn this retrospective study, performed on 417 participants, we analysed serum NfL and p-Tau181 concentrations with an ultrasensitive single molecule array (Simoa) approach. We assessed the diagnostic values of serum biomarkers in the differential diagnosis between FTLD, Alzheimer’s disease (AD) and healthy ageing; their role as markers of disease severity assessing the correlation with clinical variables, cross-sectional brain imaging and neurophysiological data; their role as prognostic markers, considering their ability to predict survival probability in FTLD.ResultsWe observed significantly higher levels of serum NfL in patients with FTLD syndromes, compared with healthy controls, and lower levels of p-Tau181 compared with patients with AD. Serum NfL concentrations showed a high accuracy in discriminating between FTLD and healthy controls (area under the curve (AUC): 0.86, p<0.001), while serum p-Tau181 showed high accuracy in differentiating FTLD from patients with AD (AUC: 0.93, p<0.001). In FTLD, serum NfL levels correlated with measures of cognitive function, disease severity and behavioural disturbances and were associated with frontotemporal atrophy and indirect measures of GABAergic deficit. Moreover, serum NfL concentrations were identified as the best predictors of survival probability.ConclusionsThe assessment of serum NfL and p-Tau181 may provide a comprehensive view of FTLD, aiding in the differential diagnosis, in staging disease severity and in defining survival probability.

show abstract

Section: Discussionsupporting

confidence: 52%

Diagnostic and prognostic value of serum NfL and p-Tau₁₈₁in frontotemporal lobar degeneration

Benussi

Karikari

Ashton

et al. 2020

J Neurol Neurosurg Psychiatry

106

112

View full text Add to dashboard Cite

show abstract

“…A recent meta-analysis showed that NFL chain protein levels both in CSF and in plasma had high diagnostic sensitivity for AD and other neurodegenerative dementias. 57 A cross-sectional, longitudinal data analysis of the Dominantly Inherited Alzheimer Network (DIAN) cohort found that CSF levels of NFL were significantly increased in mutation carriers compared to non-carriers at an estimated 6.8 years before symptom onset. Subsequent longitudinal analyses confirmed the cross-sectional findings.…”

Section: Advances In Biomarker Studiesmentioning

confidence: 99%

Early diagnosis and treatment of Alzheimer’s disease: new definitions and challenges

Pais

Martinez

Ribeiro

et al. 2020

Braz. J. Psychiatry

View full text Add to dashboard Cite

The prevalence of Alzheimer's disease (AD), a progressive neurodegenerative disorder, is expected to more than double by 2050. Studies on the pathophysiology of AD have been changing our understanding of this disorder and setting a new scenario for drug development and other therapies. Concepts like the ''amyloid cascade'' and the ''continuum of AD,'' discussed in this article, are now well established. From updated classifications and recommendations to advances in biomarkers of AD, we aim to critically assess the literature on AD, addressing new definitions and challenges that emerged from recent studies on the subject. Updates on the status of major clinical trials are also given, and future perspectives are discussed.

show abstract

“…Großes Interesse gilt aktuell dem Protein neurofilament light chain (NFL). Es handelt sich hierbei um einen Bestandteil des Zytoskeletts, welcher bei Neurodegeneration freigesetzt wird [6]. Die Freisetzung von NFL ist nicht spezifisch für die Alzheimer-Erkrankung, sondern tritt generell bei Nervenzelluntergang auf.…”

Section: Marker Für Neurodegenerationunclassified

Bluttests für die Alzheimer-Erkrankung

Jessen¹

2019

Nervenheilkunde

View full text Add to dashboard Cite

ZUSAMMENFASSUNGBislang stehen für die Darstellung der Pathologie der Alzheimer Krankheit beim Patienten Liquor- und Bildgebungsmarker zur Verfügung. Diese Methoden sind durch Invasivität bzw. Kosten limitiert. In jüngster Zeit ist es gelungen mit verschiedenen Technologie die Kernpathologie der Alzheimer Krankheit in Form des Aß1-42 bzw. der Ratio Aß1-42/Aß1-40 sowie des Tau-Proteins und des Neurofilament light chain (NFL) im Blut messbar zu machen. Aktuell handelt es sich noch um Ansätze der Forschung, es ist aber absehbar, dass diese Blutmarker in die klinische Praxis kommen werden. In dem Artikel werden aktuelle Studien zu blutbasierten Biomarkern vorgestellt, sowie zwei Initiativen, die sich mit den ethischen Implikationen der Anwendung von Alzheimer-Bluttests bei gesunden Personen beschäftigen.

show abstract

Neurofilament light chain protein in neurodegenerative dementia: A systematic review and network meta-analysis

Cited by 73 publications

References 74 publications

Diagnostic and prognostic value of serum NfL and p-Tau₁₈₁in frontotemporal lobar degeneration

Diagnostic and prognostic value of serum NfL and p-Tau₁₈₁in frontotemporal lobar degeneration

Early diagnosis and treatment of Alzheimer’s disease: new definitions and challenges

Bluttests für die Alzheimer-Erkrankung

Contact Info

Product

Resources

About

Neurofilament light chain protein in neurodegenerative dementia: A systematic review and network meta-analysis

Cited by 73 publications

References 74 publications

Diagnostic and prognostic value of serum NfL and p-Tau181in frontotemporal lobar degeneration

Diagnostic and prognostic value of serum NfL and p-Tau181in frontotemporal lobar degeneration

Early diagnosis and treatment of Alzheimer’s disease: new definitions and challenges

Bluttests für die Alzheimer-Erkrankung

Contact Info

Product

Resources

About

Diagnostic and prognostic value of serum NfL and p-Tau₁₈₁in frontotemporal lobar degeneration

Diagnostic and prognostic value of serum NfL and p-Tau₁₈₁in frontotemporal lobar degeneration